| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.90(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,779 |
31,779 |
108,516 |
523,205 |
| Total Sell Value |
$459,589 |
$703,188 |
$3,015,597 |
$13,848,977 |
| Total People Sold |
2 |
3 |
4 |
6 |
| Total Sell Transactions |
5 |
6 |
14 |
32 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hanna John Walter Jr |
Chief Commercial Officer |
• • – |
2020-07-31 |
4 |
AS |
$36.12 |
$509,145 |
D/D |
(14,095) |
74,634 |
|
56% |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• • – |
2020-07-31 |
4 |
OE |
$8.86 |
$124,882 |
D/D |
14,095 |
88,729 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• • – |
2020-07-31 |
4 |
AS |
$35.33 |
$706,694 |
D/D |
(20,000) |
80,487 |
|
56% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• • – |
2020-07-31 |
4 |
OE |
$20.21 |
$404,200 |
D/D |
20,000 |
100,487 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-30 |
4 |
AS |
$32.24 |
$366,399 |
D/D |
(11,365) |
272,207 |
|
72% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-30 |
4 |
OE |
$8.86 |
$100,694 |
D/D |
11,365 |
283,572 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-23 |
4 |
AS |
$32.04 |
$105,106 |
D/D |
(3,280) |
272,207 |
|
81% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-23 |
4 |
OE |
$8.86 |
$29,061 |
D/D |
3,280 |
275,487 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-22 |
4 |
AS |
$32.00 |
$3,200 |
D/D |
(100) |
272,207 |
|
75% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-22 |
4 |
OE |
$8.86 |
$886 |
D/D |
100 |
272,307 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-21 |
4 |
AS |
$32.09 |
$110,614 |
D/D |
(3,447) |
272,207 |
|
74% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-21 |
4 |
OE |
$8.86 |
$30,540 |
D/D |
3,447 |
275,654 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• • – |
2020-07-21 |
4 |
AS |
$32.36 |
$21,131 |
D/D |
(653) |
74,524 |
|
74% |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• • – |
2020-07-21 |
4 |
OE |
$2.40 |
$1,567 |
D/D |
653 |
75,177 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-20 |
4 |
AS |
$32.04 |
$651,911 |
D/D |
(20,349) |
272,207 |
|
71% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-07-20 |
4 |
OE |
$4.00 |
$171,287 |
D/D |
20,349 |
292,556 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• • – |
2020-07-20 |
4 |
AS |
$32.05 |
$361,993 |
D/D |
(11,294) |
74,524 |
|
71% |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• • – |
2020-07-20 |
4 |
OE |
$2.40 |
$27,106 |
D/D |
11,294 |
85,818 |
|
- |
|
| Jones Evan/ Fa |
Director |
• • – |
2020-07-15 |
4 |
AS |
$29.81 |
$301,192 |
I/I |
(10,000) |
109,653 |
|
70% |
|
| Jones Evan/ Fa |
Director |
• • – |
2020-07-14 |
4 |
AS |
$28.13 |
$566,847 |
I/I |
(20,000) |
119,653 |
|
77% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• • – |
2020-07-13 |
4 |
AS |
$28.82 |
$496,478 |
D/D |
(16,738) |
80,487 |
|
81% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• • – |
2020-07-13 |
4 |
OE |
$5.98 |
$218,373 |
D/D |
16,738 |
97,225 |
|
- |
|
| Epstein Robert S |
Director |
• • – |
2020-07-13 |
4 |
AS |
$28.74 |
$297,252 |
D/D |
(10,000) |
0 |
|
81% |
|
| Epstein Robert S |
Director |
• • – |
2020-07-13 |
4 |
OE |
$5.28 |
$52,800 |
D/D |
10,000 |
10,000 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• • – |
2020-07-06 |
4 |
AS |
$28.21 |
$2,276,172 |
D/D |
(80,677) |
119,632 |
|
63% |
|
557 Records found
|
|
Page 11 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.40 (1.77%) 
